RYZNEUTA (efbemalenograstim alfa-vuxw)
Ryzneuta (efbemalenograstim alfa-vuxw) is a leukocyte growth factor indicated to decrease the incidence of infection, manifested as febrile neutropenia, in adult patients. It is used specifically for patients with non-myeloid malignancies who are receiving myelosuppressive anti-cancer drugs associated with a significant risk of febrile neutropenia. This therapy is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.
How RYZNEUTA Works
Efbemalenograstim alfa-vuxw is a colony-stimulating factor that acts on hematopoietic cells by binding to specific cell surface receptors. This binding process stimulates the proliferation, differentiation, and commitment of these cells. Furthermore, the drug promotes the functional activation of end cells to support the patient's immune response during chemotherapy.
Details
- Status
- Prescription
- First Approved
- 2023-11-16
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
RYZNEUTA Approval History
What RYZNEUTA Treats
2 indicationsRYZNEUTA is approved for 2 conditions since its original approval in 2023. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Febrile Neutropenia
- Non-Myeloid Malignancies
RYZNEUTA Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
What's emerging in RYZNEUTA's indications
See all emerging drugs →Phase 3 candidates targeting molecules with no FDA-approved drug, in indications RYZNEUTA treats. First-in-class if their pivotal trials read out positive.
Drugs Similar to RYZNEUTA
3 of 19FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
RYZNEUTA FDA Label Details
Indications & Usage
FDA Label (PDF)RYZNEUTA is indicated for the treatment of Febrile Neutropenia; Non-Myeloid Malignancies.
Track RYZNEUTA with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.